Enhertu significantly improved invasive disease-free survival when compared with Kadcyla in high-risk HER2-positive early breast cancer.
Cedars-Sinai Cancer | Strategic Alliance Partners
Latest from Cedars-Sinai Cancer
An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.
Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.
An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.
Advertisement
Advertisement
Trending on CURE
1
A Survivor's 30-Year Wait for Lymphedema Relief Ends with Hackensack's New Supermicrosurgery Robotic Procedure
2
Gastrointestinal Stromal Tumor: Comprehensive Patient Guide
3
Jakafi Trial Shows Benefits for Patients with Myelofibrosis and Anemia
4
FDA Grants Orphan Drug Designation to MNV-201 for Myelodysplastic Syndrome
5
